Annual diabetes screening questioned:
This article was originally published in Clinica
Research published in the Journal of the American Medical Association (JAMA) has questioned the benefits of annual eye-screening for type II diabetes, compared with less frequent screening intervals, especially in low-risk patients. The study, from the University of Michigan, Ann Arbor (JAMA, February 16) sets out to evaluate the cost-effectiveness of various screening intervals, stratified by age and level of glycaemic control. The study concludes that, on a cost-effectiveness basis, annual screening for all patients without previously detected retinopathy may not be warranted, but should be tailored according to individual circumstances. Universal quality-of-care standards should therefore be based on a careful assessment of costs versus benefits, it said.
You may also be interested in...
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.